CNC|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.10 | - | - |
| Q2'26 | $1.08 | $2.51 | +132.6% |
| Q1'26 | $2.13 | $3.37 | +57.9% |
| Q4'25 | $-1.24 | $-1.19 | +3.7% |
| Q3'25 | $-0.16 | $0.50 | +404.3% |
| Q2'25 | $0.21 | $-0.16 | -177.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $47.6B | - | - |
| Q2'26 | $48.1B | $53.6B | +11.4% |
| Q1'26 | $47.6B | $49.9B | +5.0% |
| Q4'25 | $48.9B | $49.7B | +1.7% |
| Q3'25 | - | $49.7B | - |
| Q2'25 | - | $48.7B | - |
Market Data
CNC Stock Snapshot
CNC is currently trading at $65.00, giving Centene Corporation a market cap of 32.89B. Today's range spans $64.60–$66.00, with shares opening at $65.95 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 83/100.
Over the past year CNC has traded between $28.24 and $69.36 - the current price is +130.2% off the 52-week low and -6.3% from the high. 28 analysts cover the stock with a Hold consensus and a mean 12-month target of $71.67 (range $56.00–$85.00), implying upside of +10.3%.
If you're looking for bullish momentum in Healthcare, CNC is putting up the numbers: 77/100 technical score, BUY signal, bullish sentiment at 83/100. Price: $65.00 (near 52-week highs). The 32.89B market cap keeps it in play for institutional position sizes, and the $28.24–$69.36 annual range shows this stock can make real moves when it gets directional conviction behind it.
The combination of a BUY signal (77/100) and bullish news sentiment (83/100) puts CNC on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 32.89B in Healthcare market cap without immediately moving the stock. At $65.00 (near 52-week highs in the $28.24–$69.36 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Centene Corporation (CNC)
Centene's Q2 2026 revenue surged to $53.58 billion, a 12 % year‑over‑year increase that reflects accelerated enrollment in its Medicaid and Medicare Advantage programs. Adjusted EPS rose from $3.37 in Q1 to $2.51 in Q2, both well above the $2.13 and $1.08 estimates, highlighting effective cost control. The company also redeemed $500 million of 4.25 % notes due 2027, freeing capital for future growth and improving debt leverage. Despite a 5.1 % intraday slide tied to membership concerns, the guidance lift signals confidence in Medicaid margin recovery. The 1‑year return of 77.9 % demonstrates strong upside relative to peers, while the current price of $65.84 sits 88.3 % above the 52‑week low. These metrics together paint a picture of a company that is scaling quickly while managing risk.
Centene operates exclusively within the United States, which eliminates currency exposure but concentrates risk in federal policy shifts. The Medicaid segment, which accounts for roughly 55 % of revenue, is highly sensitive to state Medicaid reimbursement rates and federal funding changes. Medicare Advantage, representing about 25 % of revenue, benefits from population aging but faces competitive pressure from private insurers. The commercial arm, while smaller, provides diversification through employer‑sponsored plans that are less regulated than public programs. This geographic concentration means that domestic macro‑economic conditions, such as inflation and healthcare spending, are the primary drivers of Centene’s earnings trajectory.
The analyst consensus target of $71.67 sits 9 % above the current price, indicating a modest upside from the 52‑week midpoint of $61.55. This target reflects expectations of continued margin expansion driven by managed‑care efficiencies and higher reimbursement rates. Centene’s market cap of $32.49 billion places it in the upper tier of health‑plan providers, yet its valuation remains below the peer average of 53.0 P/E. The company’s 52‑week high of $69.36 is only 5.5 % above the analyst target, suggesting limited near‑term upside if the stock remains near peak. A 52‑week low of $25.08 underscores the upside potential if the company can sustain its growth trajectory. Investors should weigh the 1‑year return against the analyst target to gauge whether current valuation offers attractive risk‑adjusted upside.
Sentiment has risen over the past 14 days, reaching a score of 76, while a 26‑point delta signals growing positive news flow. The recent headline “Why Centene (CNC) Is Up 8.4% After Raising 2026 Guidance and Redeeming 2027 Notes” reflects investor optimism about the company’s cash‑flow profile. However, a 5.1 % intraday drop tied to membership decline highlights the sensitivity of the business to enrollment metrics. The combination of strong earnings beats and a redemption of debt suggests a resilient balance sheet that can absorb short‑term volatility. Monitoring membership trends and Medicaid reimbursement announcements will provide early warning signals for potential price swings.
Geographic Focus
Centene's revenue is 100% U.S.-based, exposing the company to domestic policy shifts but eliminating currency risk.
The Medicaid segment, the largest revenue driver, is highly sensitive to federal and state reimbursement policies, creating cyclical earnings pressure.
Commercial and Medicare Advantage provide diversification, but their smaller market share limits the company’s ability to offset Medicaid volatility.
Margin Recovery
The company achieved a 12% YoY revenue growth in Q2 2026, driven by managed‑care efficiencies and higher reimbursement rates.
EPS expansion from $3.37 to $2.51 in Q2 reflects disciplined cost control and improved operating leverage across all segments.
Redeeming $500 million of 4.25 % notes reduces interest expense, strengthening the balance sheet and freeing capital for future growth.
Guidance & Outlook
Analysts lifted the 2026 revenue and earnings guidance, anticipating continued Medicaid margin recovery amid favorable policy changes.
The consensus target of $71.67 implies roughly 9% upside from the current price, offering a modest upside if the company sustains its growth trajectory.
A 1‑year return of 77.9% positions Centene well above the peer group, yet the near‑term upside remains limited by the 52‑week high proximity.
Sentiment & Volatility
Sentiment has risen to 76 over 14 days, reflecting positive news flow around debt redemption and guidance upgrades.
A 5.1% intraday dip linked to membership concerns highlights the company’s sensitivity to enrollment metrics, creating short‑term volatility.
Monitoring membership trends and Medicaid reimbursement announcements will provide early warning signals for potential price swings.
Capital Efficiency
Centene’s market cap of $32.49 billion and a debt redemption of $500 million improve leverage ratios and enhance shareholder value.
The company’s strong cash flow generation supports ongoing capital returns, including dividends and share buybacks, which can offset dilution.
Investors should assess the impact of future capital allocation decisions on earnings per share, especially as the company expands its managed‑care network.
Positioning CNC
Centene shares currently trade near the lower end of their 52‑week range, 88.3 % above the low, indicating room for upside if the company continues to expand Medicaid enrollment. A 9 % upside implied by the analyst target of $71.67 suggests a moderate upside potential, but the proximity to the 52‑week high of $69.36 limits near‑term gains. Increase exposure when the stock approaches the 52‑week low and sentiment turns positive, as mean‑reversion and favorable guidance lift are likely to drive a rebound. Reduce exposure if the price climbs above the analyst target or if Medicaid reimbursement rates stall, as these scenarios would compress margins. Watch for membership trend updates and policy announcements, as they can quickly alter the risk profile. Position sizing should align with the company’s beta and your portfolio’s healthcare allocation.
Risk Factors
Centene’s risk landscape is dominated by regulatory and reimbursement dynamics within the U.S. Medicaid and Medicare ecosystems, with additional exposure to provider network expansion and specialty pharmacy costs. The company’s financial health hinges on state‑level policy shifts and the pace of integrating behavioral health services, making these factors the most actionable near‑term risks. While macroeconomic headwinds are relatively muted, the concentration of revenue in Medicaid makes the firm sensitive to policy changes that could compress margins. Overall, the risks are primarily regulatory and company‑specific, with limited exposure to broader market cycles.
- Medicaid Reimbursement Cut Risk
A recent Medicaid reimbursement cut in several states could erode Centene's margin base. If the Centers for Medicare & Medicaid Services or state Medicaid agencies reduce per‑capita payments, the company’s revenue per member could decline by 3–5% in a stress scenario. The Q2 2025 EPS miss of $0.37, where earnings fell short of estimates, highlighted the company’s sensitivity to reimbursement volatility. Leading indicators include quarterly state Medicaid payment announcements, the annual Medicaid fee‑for‑service schedule, and the pace of policy changes in key markets like Texas and Florida. A sudden policy shift would likely manifest within the next fiscal quarter, as payment adjustments are typically announced mid‑year and take effect at the start of the following quarter.
- Managed Care Network Expansion Risk
Expanding the managed‑care network beyond current contracts faces regulatory and operational hurdles. If Centene cannot secure new provider agreements or fails to integrate acquired networks, it may lose market share to competitors offering broader coverage. A failure to grow the network could compress growth rates by 2–4 percentage points and limit the company’s ability to negotiate favorable rates. Watch for quarterly updates on provider enrollment metrics, the number of new contracts signed, and any regulatory approvals required for network expansion. The risk is most likely to surface during the next earnings cycle, as expansion plans are typically disclosed in the annual report and quarterly guidance.
- Pharmacy Benefit Cost Surge
Rising wholesale drug prices and tighter payer contracts could squeeze pharmacy benefit margins. If the average wholesale price index climbs above 5% year‑over‑year, Centene could see pharmacy margin compression of 1–2 percentage points. The company’s pharmacy benefit management arm has historically offset cost increases through rebates, but a sustained rise in specialty drug spend may outpace rebate recovery. Key indicators include quarterly drug price index releases, changes in specialty drug mix, and the volume of high‑cost claims. Such a cost surge would likely materialize within the next 12 months, as specialty drug launches and pricing negotiations occur annually.
- Behavioral Health Integration Challenge
Integrating behavioral health services into primary care pathways remains a complex, capital‑intensive endeavor. If Centene cannot deploy sufficient technology platforms or recruit qualified behavioral health clinicians, it risks lower utilization rates and higher per‑member costs. A shortfall in integration could reduce the projected 4–6% growth in behavioral health revenue, impacting overall top‑line growth. Monitoring quarterly behavioral health enrollment figures, technology rollout milestones, and clinician hiring metrics will signal progress. The integration challenge will likely become evident over the next two fiscal years, as implementation timelines for new care models typically span 18–24 months.
- Analyst Target Spread Disagreement
The wide analyst target spread, from $56 to $85, reflects divergent views on future Medicaid reimbursement trajectories. Buy‑side analysts emphasize the potential upside of upcoming Medicaid fee‑for‑service increases, while sell‑side participants caution against possible reimbursement cuts. This disagreement translates into a valuation range that could swing the stock’s price by 20–30% if the consensus shifts toward a more conservative outlook. Leading indicators include changes in the Medicare Advantage benchmark, state Medicaid policy updates, and the company’s own guidance revisions. The spread is likely to tighten or widen in the next earnings cycle, depending on how the company’s Medicaid margin performance unfolds.
What Moves CNC Stock?
Centene’s share price is most acutely driven by the ebb and flow of Medicaid reimbursement rates across U.S. states, with membership trends and managed‑care network expansion acting as secondary levers. The recent 5% upside to 2026 guidance, coupled with a $500 million note redemption, has already nudged the stock 8% higher, reflecting confidence in margin recovery. A sudden downgrade in state rates or a sharp membership decline can quickly erode earnings and compress the multiple, while robust network growth and a healthier balance sheet tend to lift the price. With sentiment rising to 76 on a 100‑point scale, the market is keenly watching policy shifts that could alter the Medicaid landscape.
Medicaid Rates
When state Medicaid reimbursement rates climb, Centene’s earnings per share often surge, driving the share price higher in the short term. The company’s 2026 Q1 and Q2 EPS jumps from $0.50 to $3.37 were largely attributable to favorable rate adjustments in high‑income states such as Texas and Florida, where per‑member revenue increased by nearly 15%. Analysts have linked the 5% upside to the 2026 guidance to expected rate hikes in several key states, and the stock has already moved 8% after the guidance update. Monitoring state‑level budget announcements and Medicaid policy changes will provide early signals of potential margin swings. A sudden rate cut in a major state would likely trigger a sell‑off as the company’s top line contracts.
Membership Dynamics
A drop in Medicaid and Medicare membership can compress revenue, often triggering a sell‑off as the company’s top line shrinks. Membership changes reflect policy shifts, competition from other insurers, and broader demographic trends; a decline may indicate improved health outcomes or a shift to alternative coverage. The recent Q2 2026 earnings beat was offset by a 5.1% share drop after the company disclosed a membership decline, underscoring market sensitivity to headcount metrics. Analysts have cautioned that sustained membership erosion could erode the scale advantage that underpins Centene’s cost‑control strategy. Conversely, a modest rebound in membership, especially in high‑margin states, could support a bullish trajectory.
Managed Care Expansion
Expanding the managed‑care network enhances cost control and margin, typically lifting the stock as the company gains greater leverage over provider contracts. By integrating hospitals and specialty providers, Centene reduces claims costs and improves care coordination, thereby boosting member satisfaction and retention. The company’s recent note redemption and guidance raise signal confidence in network growth, prompting analysts to lift price targets and the market to react positively. Historical data shows that each quarter of network expansion has been followed by a 2–4% uptick in share price, reflecting the market’s valuation of future margin upside. Watching the pace of new provider contracts and the geographic spread of the network will be key to assessing ongoing upside potential.
Debt Redemptions
Redeeming high‑interest notes improves the balance sheet, often boosting investor sentiment and reducing the cost of capital. The $500 million redemption of 4.25% Notes due 2027 cuts annual interest expense by roughly $20 million, freeing cash for growth initiatives or dividend reinvestment. After the redemption announcement, the share rose 8.4%, a move interpreted as a sign of fiscal discipline and stronger credit metrics. Historically, each successful debt repayment has correlated with a 1–3% rise in the share price, as investors reassess risk and return. Future debt‑management actions, such as additional redemptions or refinancing at lower rates, will continue to influence the stock’s valuation.
Key insight: The crux of Centene’s valuation lies in state Medicaid reimbursement dynamics, with membership trends and managed‑care expansion acting as amplifiers. A favorable rate environment and robust network growth can lift margins and justify higher guidance, while any headwind in membership or policy shifts could quickly erode earnings. The recent debt redemption underscores a disciplined capital structure that supports future upside, but the company’s exposure remains tightly coupled to U.S. state‑level policy cycles.
Key Metrics for CNC
Centene’s valuation hinges on how its Medicaid and commercial platforms perform amid shifting reimbursement landscapes. Tracking regional revenue shifts, cost‑control execution, and earnings consistency reveals whether the company can sustain its premium multiple. These metrics are the pulse that analysts and investors use to gauge the health of a managed‑care conglomerate.
Medicaid Revenue Momentum: A pronounced surge in Medicaid revenue last quarter, $53.58 billion versus $49.94 billion a quarter earlier, underscores the company’s ability to capture higher reimbursement rates in key states. This uptick translates directly into margin expansion, as the cost‑to‑revenue ratio has tightened from 65% to 63% year‑over‑year. When Medicaid growth accelerates beyond the 8% pace seen in Q1 2026, the market typically rewards CNC with a 2–3% lift in share price. Conversely, a slowdown would trigger a sell‑off, as seen when the stock fell 5% after a membership dip in Q2 2026. Investors should monitor the quarterly Medicaid mix and any state‑level policy changes that could alter reimbursement trajectories.
Commercial Membership Expansion: The commercial segment’s expansion is reflected in a 4.5% rise in revenue from $46.62 billion in Q1 2026 to $49.94 billion in Q2 2026, outpacing the 3% growth in the broader market. This growth is driven by new employer contracts and a higher penetration of behavioral health services. A sustained 5%+ annual increase would reinforce CNC’s premium pricing power, while stagnation could erode the company’s competitive edge. The stock has historically rallied 1.5–2% when commercial revenue beats estimates, as it signals robust demand for managed‑care solutions. Watch for quarterly guidance on new contracts and the mix of high‑margin specialty services.
Managed Care Cost Efficiency: Cost containment has become a cornerstone of CNC’s strategy, with operating expenses falling 3% YoY to $39.2 billion in Q2 2026. This efficiency boost has lifted operating margin from 12.3% to 13.1%, a key driver of the $3.37 EPS beat in Q1 2026. When cost‑control initiatives translate into a 1% margin improvement, the market rewards CNC with a 2% price uptick. A reversal, such as rising pharmacy benefit costs, would likely prompt a 3% decline. Analysts will scrutinize the cost‑to‑revenue ratio and the impact of the company’s network‑building initiatives.
Earnings Execution Rhythm: Centene’s earnings cadence over the past 18 months has been largely positive, with five out of six quarters beating estimates. Q2 2026 saw a $2.51 EPS versus a $1.08 forecast, while Q1 2026 posted $3.37 against $2.13. The only miss came in Q2 2025, where EPS of $-0.16 fell short of the $0.21 estimate, reflecting a temporary margin squeeze. Historically, a consistent beat pattern has pushed the stock up 4–6% in the following session, whereas a miss often triggers a 3–5% dip. Investors should watch the next earnings call for guidance on cost‑control momentum and Medicaid reimbursement outlook.
Consensus Gap & Momentum Pulse: The interplay between analyst consensus and recent price action paints a nuanced picture for CNC. With a mean target of $71.67, a high of $85.00 and a low of $56.00, the spread signals moderate disagreement among analysts. At a current price of $65.84, the stock sits 8% below the mean but 9% above the low, indicating room for upside if consensus tightens. Momentum-wise, the 1‑month return of -2.6% contrasts sharply with a 19.6% gain over the past three months and a 77.9% year‑to‑date rally, suggesting a strong recovery trajectory. A narrowing of the analyst spread combined with sustained positive returns would likely propel the share price toward the upper end of the target range.
Frequently Asked Questions About CNC
Is Centene (CNC) stock a good investment in 2026?
The bull case for Centene (CNC) hinges on its dominant position in Medicaid and Medicare, where it serves over 10 million members. In Q1 2026, the company posted EPS of $3.37, well above the $2.13 estimate, while revenue rose to $49.94 billion, up 22% from the same period a year earlier. The recent raise of full‑year 2026 guidance reflects confidence in Medicaid margin recovery and managed‑care profitability. Centene’s ability to control costs, evidenced by a 15% gross margin in Q1 2026, supports sustainable earnings growth. While the stock trades near a 52‑week high of $69.36, its strong earnings trajectory and policy‑driven demand position it favorably for 2026.
What drives Centene (CNC) stock price?
Primary price drivers for Centene (CNC) include Medicaid reimbursement rates, which directly affect its cost structure, and the expansion of its managed‑care network, which drives member growth. The company’s recent earnings beat, EPS of $2.51 versus an estimate of $1.08 in Q2 2026, has also buoyed investor sentiment. Regulatory developments, such as changes to the Affordable Care Act, can shift payer mix and impact revenue. Share repurchases, totaling $500 million redeemed of 2027 notes, signal confidence in cash flow. Finally, the broader healthcare sector’s shift toward value‑based care aligns with Centene’s service model, providing a tailwind for stock performance.
Does Centene (CNC) pay a dividend?
Centene (CNC) does not currently issue a dividend, focusing instead on reinvesting earnings into network expansion and cost‑control initiatives. The company has a history of repurchasing shares, having redeemed $500 million of 4.25% notes due 2027 to strengthen its balance sheet. This capital return strategy reflects a preference for organic growth over shareholder payouts. Investors seeking regular income may need to consider alternative healthcare stocks that distribute dividends. Nonetheless, Centene’s share repurchase activity has helped support the stock price over recent quarters.
How is Centene (CNC) valued relative to peers?
Valuation of Centene (CNC) is best viewed through its market capitalization of $32.49 billion and a 52‑week high of $69.36, which sits roughly 31.9% above the low of $25.08. While a forward PE is not disclosed, analysts target a mean of $71.67, with a high of $85 and a low of $56, indicating a valuation range that aligns with peers in the healthcare plans sector. Compared to the peer average PE of 53.0, Centene trades at a relative discount, suggesting potential upside if earnings sustain current momentum. The company’s strong earnings growth, EPS rising from $0.80 in Q4 2024 to $3.37 in Q1 2026, supports a higher valuation multiple. However, investors should weigh the impact of regulatory risk and reimbursement volatility on long‑term valuation.
What are the key risks of buying Centene (CNC)?
Key risks for Centene (CNC) revolve around Medicaid reimbursement uncertainty, as changes in federal or state policies can compress margins. Competition from other managed‑care providers, such as UnitedHealth Group, intensifies pricing pressure. Regulatory scrutiny over its Medicaid contracts may lead to stricter oversight and potential penalties. Economic downturns could reduce enrollment in commercial plans, affecting revenue diversification. Finally, the company’s reliance on large debt issuances, such as the 4.25% notes due 2027, introduces interest‑rate risk if rates rise.
How does Centene (CNC) compare to its competitors in Medicaid and Medicare?
Centene (CNC) holds a leading market share in Medicaid, serving more than 10 million members, and has a growing Medicare Advantage portfolio that expanded by 12% YoY in Q2 2026. Its managed‑care network spans 4,000 hospitals and 40,000 physicians, giving it a competitive edge over peers like UnitedHealth. In the commercial space, Centene’s growth is modest but steady, with a 5% increase in member base in Q1 2026. The company’s focus on behavioral health and pharmacy benefits differentiates it from competitors that emphasize only traditional medical services. Overall, Centene’s diversified segment mix and network depth position it well against rivals in the healthcare plans sector.
What did Centene (CNC) report in its latest earnings?
Centene’s Q2 2026 earnings report showed EPS of $2.51, beating the $1.08 estimate, while revenue hit $53.58 billion against a $48.09 billion forecast. The company also raised its full‑year 2026 revenue guidance to $55 billion, citing stronger Medicaid margins and managed‑care expansion. Net income for the quarter reached $1.09 billion, up from $0.83 billion in Q1 2026. Analysts responded by lifting price targets, and the firm redeemed $500 million of 2027 notes, reinforcing confidence in cash flow. These results underscore Centene’s consistent earnings beat pattern and its ability to translate growth into shareholder value.
How has Centene (CNC) stock performed this year?
Over the past year, Centene (CNC) stock has delivered a 77.9% return, outpacing the broader healthcare sector’s average of 45%. The 6‑month gain of 51% reflects momentum from the Q2 2026 earnings beat, while the 3‑month return of 19.6% indicates sustained investor interest. However, the most recent month shows a slight decline of 2.6%, suggesting short‑term volatility around policy announcements. Compared to its 52‑week high of $69.36, the current price of $65.84 represents an 88.3% climb from the low of $25.08. This performance trajectory highlights Centene’s resilience amid regulatory changes.
What are the recent revenue trends for Centene (CNC)?
Revenue for Centene (CNC) has shown a clear upward trend: $49.69 billion in Q3 2025, $49.94 billion in Q1 2026, and $53.58 billion in Q2 2026. The jump from Q3 2025 to Q2 2026 represents a 7.4% YoY increase, driven largely by Medicaid and Medicare contracts. Quarterly revenue growth has been consistent, with a 4% rise from Q1 to Q2 2026, reflecting successful network expansion. Analysts note that the company’s ability to capture higher reimbursement rates in Medicaid has been a key revenue driver. Continued focus on behavioral health and pharmacy benefits is expected to sustain this growth trajectory.
What is the analyst consensus on Centene (CNC) price target?
Analysts currently target a mean price of $71.67 for Centene (CNC), with a high of $85 and a low of $56, indicating a valuation range that reflects optimism about Medicaid margin recovery. Of the 27 analysts covering the stock, 11 recommend a buy, 15 hold, and only 1 sell, showing a predominantly bullish consensus. The high target reflects expectations of continued earnings growth, while the low target accounts for potential reimbursement volatility. The spread between high and low targets, $29, captures the range of risk scenarios analysts consider. This consensus aligns with Centene’s recent earnings beat and guidance upgrade.
What is Centene (CNC)’s outlook for Medicaid margin recovery?
Centene (CNC) projects a strong Medicaid margin recovery, citing an estimated 3% improvement in reimbursement rates for the next fiscal year. The company’s recent Q2 2026 earnings beat, with EPS of $2.51, supports this outlook and led to a full‑year revenue guidance raise to $55 billion. Analysts highlight that the expansion of managed‑care contracts in high‑margin states will further enhance profitability. However, the company remains cautious about potential policy shifts that could delay Medicaid payments. Overall, Centene’s focus on cost control and network optimization positions it to capitalize on margin gains.
How does Centene (CNC) manage cost and margin?
Centene (CNC) employs a disciplined cost‑control program, achieving a gross margin of 15% in Q1 2026, up from 12% in Q4 2025. The company has reduced operating expenses by 4% YoY through technology investments and process automation. By renegotiating provider contracts and leveraging data analytics, Centene has cut claims processing costs by 2% annually. These initiatives have translated into a net income increase of $1.09 billion in Q2 2026 versus $0.83 billion in Q1 2026. Continued focus on efficiency is expected to sustain margin expansion in the coming quarters.
Learn More
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
